SCHEMBL12467967

SCHEMBL12467967

BN(C)c1ccc(-c2cc(N=O)c3ccccc3n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.43
SLC2A1 P11166 1/20 0.42
DHODH Q02127 2/20 0.42
LMNA P02545 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
ACP1 P24666 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HPGD P15428 3/20 0.40
PDE10A Q9Y233 1/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 3/20 0.40
POLB P06746 1/20 0.40
ACACA Q13085 1/20 0.40
ACHE P22303 1/20 0.40
HTT P42858 1/20 0.40
TSHR P16473 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP1A2 P05177 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12467969 0.80 CYP19A1 (0.47) CYP3A4SLC2A1DHODHLMNASMN1; SMN2
SCHEMBL17688770 0.69 ACP1 (0.65) CYP3A4LMNASMN1; SMN2ACP1KDM4E
SCHEMBL15237514 0.69 CYP1A2 (0.58) SMN1; SMN2KDM4EHPGDALDH1A1MAPT
SCHEMBL484152 0.68 CYP3A4 (0.54) CYP3A4LMNASMN1; SMN2ACP1KDM4E
SCHEMBL6534399 0.68 CYP3A4 (0.54) CYP3A4LMNASMN1; SMN2ACP1KDM4E
SCHEMBL28459418 0.68 DHODH (0.74) CYP3A4DHODHLMNASMN1; SMN2KDM4E
SCHEMBL13568539 0.68 CYP3A4 (0.53) CYP3A4DHODHLMNASMN1; SMN2ACP1
SCHEMBL14696946 0.66 LMNA (0.75) CYP3A4DHODHLMNASMN1; SMN2ACP1
SCHEMBL12324217 0.66 MAPT (0.54) CYP3A4LMNASMN1; SMN2ACP1KDM4E
SCHEMBL483403 0.66 CYP3A4 (0.48) CYP3A4DHODHLMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 CYP3A4 4408/4885SLC2A1 2076/4885DHODH 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.